Endocrine Abstracts

UK National Acromegaly Register collects data on routine clinical practice in 34 centres. We analysed all GH and IGF1 data to assess adequacy of control & responses to medical treatment (Rx) with somatostatin analogs (SMS) & dopamine agonists (DA). Methods: Under program control, GH records (basal, profile or GTT) were correlated with IGF1, tumour size, Rx, surgery (TSS) & radiotherapy (RT) in the database, then processed in Excel to derive summary data for each patient & each course of Rx, stratified by era. GH considered controlled if ≤2μg/L or ≤5mU/L. Results: 29,181 GH records were identified in 2572 patients (50% ♂). 70% patients had TSS, 45% RT; 41% received SMS (35% as monotherapy) & 41% DA (36%). Median latest GH (μg/L) was 1.2 overall, 1.8 on Rx & 2.1 off Rx. In 2000’s considering every GH/IGF1 in 1715 courses of Rx: mean %age of GH/IGF1/Both controlled was 57/51/39% SMS, 50/36/26% DA & 44/34/20% SMS+DA combined. For latest Rx of >360d duration control was 75/69/55% SMS, 77/55/45% DA & 50/51/32% SMS+DA. Drug preparations were compared. Conclusions: GH and IGF1 control is improving with time but control of both is still only achieved in a minority, even on Rx. SMS and DA can both achieve control in a useful proportion of patients, but not in all.

Declaration of interest: There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding: No specific grant from any funding agency in the public, commercial or not-for-profit sector.

Control of Latest GH and IGF1 on and off Rx